Literature DB >> 6259260

Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum.

D P Beebe, N R Cooper.   

Abstract

Neutralization of VSV by human serum ws previously shown to involve C1, C2, C3, and C4 of the classical complement (C) pathway. All normal human sera tested were equivalently active in this regard. However, purified C1, C2, C3, and C4 were unable to mediate VSV neutralization. In the present studies an additional factor required for C-mediated neutralization was isolated from normal human serum and identified as a natural IgM antibody specific for a viral encoded antigen. Purified IgM bound to the virus and formed a complex that activated component C1. Normal serum concentrations of purified IgM, C1, C2, C3, C4 neutralized VSV to the same extent as normal serum. Purified IgM did not neutralize VSV alone or in conjunction with C1, C2, and C4. Inclusion of C3 resulted in full neutralization and C3b binding to the virus was demonstrated. Thus, normal human serum contains a natural antibody of the IgM class that is directed toward a viral antigen. The antibody facilitates neutralization by forming an immune complex that activates C1 and thus efficiently initiates the classical pathway at the viral surface. Neutralization occurs with C3b deposition on the viral envelope and probably results from a blanket of C protein that interferes with viral attachment to susceptible cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6259260

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

Review 1.  Systemic lupus erythematosus: RNA-protein autoantigens, models of disease heterogeneity, and theories of etiology.

Authors:  J B Harley; R H Scofield
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

2.  Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.

Authors:  Erin Mehlhop; Camilo Ansarah-Sobrinho; Syd Johnson; Michael Engle; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-12-13       Impact factor: 21.023

3.  A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes.

Authors:  D S Ory; B A Neugeboren; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

4.  PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice.

Authors:  Mulu Z Tesfay; Amber C Kirk; Elizabeth M Hadac; Guy E Griesmann; Mark J Federspiel; Glen N Barber; Stephen M Henry; Kah-Whye Peng; Stephen J Russell
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

5.  Retargeting vesicular stomatitis virus glycoprotein pseudotyped lentiviral vectors with enhanced stability by in situ synthesized polymer shell.

Authors:  Min Liang; Ming Yan; Yunfeng Lu; Irvin S Y Chen
Journal:  Hum Gene Ther Methods       Date:  2013-02       Impact factor: 2.396

6.  Autoantigenicity of Ro/SSA antigen is related to a nucleocapsid protein of vesicular stomatitis virus.

Authors:  R H Scofield; J B Harley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

7.  Regulation of human natural killing by lysosomotropic and thiol-reactive agents.

Authors:  H Shau; J R Dawson
Journal:  Immunology       Date:  1985-08       Impact factor: 7.397

8.  Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement.

Authors:  Zhili Xu; Qi Qiu; Jie Tian; Jeffrey S Smith; Gina M Conenello; Takashi Morita; Andrew P Byrnes
Journal:  Nat Med       Date:  2013-03-24       Impact factor: 53.440

9.  Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement.

Authors:  G R Nemerow; F C Jensen; N R Cooper
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

Review 10.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.